Veracyte, Inc. (VCYT)
Largest Insider Buys in Sector
VCYT Stock Price History Chart
VCYT Stock Performance
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, …
Insider Activity of Veracyte, Inc.
Over the last 12 months, insiders at Veracyte, Inc. have bought $0 and sold $4.06M worth of Veracyte, Inc. stock.
On average, over the past 5 years, insiders at Veracyte, Inc. have bought $525,242 and sold $44.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $980,094 was made by Stapley Marc (Chief Executive Officer) on 2022‑06‑10.
List of Insider Buy and Sell Transactions, Veracyte, Inc.
| 2024-09-19 | Sale | director | 5,173 0.0067% | $35.23 | $182,263 | -3.62% | ||
| 2024-09-04 | Sale | Chief Commercial Officer-CLIA | 5,479 0.0072% | $29.78 | $163,159 | +14.33% | ||
| 2024-08-13 | Sale | director | 24,326 0.0341% | $32.04 | $779,456 | +6.20% | ||
| 2024-08-13 | Sale | director | 47,645 0.0671% | $32.20 | $1.53M | 0.00% | ||
| 2024-08-12 | Sale | director | 200 0.0003% | $30.00 | $6,001 | +10.71% | ||
| 2024-08-09 | Sale | director | 1,778 0.0024% | $30.03 | $53,391 | +13.15% | ||
| 2024-08-07 | Sale | director | 5,108 0.0075% | $30.32 | $154,883 | +21.89% | ||
| 2024-08-07 | Sale | director | 5,000 0.007% | $29.00 | $145,000 | +21.89% | ||
| 2024-07-16 | Sale | Chief Commercial Officer-CLIA | 1,277 0.0019% | $25.00 | $31,925 | +25.20% | ||
| 2024-07-16 | Sale | director | 7,500 0.0109% | $25.00 | $187,500 | +25.20% | ||
| 2024-07-16 | Sale | director | 5,000 0.0071% | $24.50 | $122,500 | +25.20% | ||
| 2024-06-11 | Sale | director | 3,870 0.0049% | $20.59 | $79,683 | +48.54% | ||
| 2024-06-10 | Sale | director | 3,870 0.0049% | $20.32 | $78,634 | +51.44% | ||
| 2024-06-07 | Sale | director | 2,500 0.0033% | $20.97 | $52,425 | +52.95% | ||
| 2024-05-28 | Sale | director | 1,539 0.002% | $21.00 | $32,319 | +40.40% | ||
| 2024-04-01 | Sale | director | 10,000 0.0133% | $21.65 | $216,528 | +6.19% | ||
| 2024-03-01 | Sale | director | 10,000 0.0135% | $24.36 | $243,599 | -6.17% | ||
| 2023-07-19 | Sale | director | 3,928 0.0056% | $30.17 | $118,490 | -19.54% | ||
| 2023-07-18 | Sale | director | 9,765 0.0137% | $30.18 | $294,706 | -20.68% | ||
| 2023-07-18 | Sale | director | 10,000 0.0142% | $30.50 | $305,000 | -20.68% |
Insider Historical Profitability
| Holstein Jens | director | 27878 0.0363% | $36.49 | 1 | 3 | +12.01% |
| Stapley Marc | Chief Executive Officer | 159761 0.208% | $36.49 | 1 | 0 | +45.22% |
| Anderson Bonnie H | director | 42681 0.0556% | $36.49 | 4 | 51 | +38.63% |
| Brooks Julie | EVP,General Counsel, Secretary | 3122 0.0041% | $36.49 | 4 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $163.65M | 9.66 | 7.38M | +3.75% | +$5.91M | <0.01 | |
| Wellington Management Company | $163.26M | 9.64 | 7.37M | +4.23% | +$6.63M | 0.03 | |
| BlackRock | $159.8M | 9.43 | 7.21M | +0.69% | +$1.1M | <0.01 | |
| ARK Investment Management LLC | $156.07M | 9.21 | 7.04M | -8.01% | -$13.58M | 0.54 | |
| State Street | $95.89M | 5.66 | 4.33M | +39.19% | +$27M | <0.01 |